Type 2 diabetes and metabolic fatty liver disease cluster in the same postcodes, and the clustering is not random. The biology of insulin resistance explains why the same diagnosis, made at the same age, carries a different prognosis depending on where a patient lives and what they can afford to change.

The Postcode as a Liver Signal

Glasgow's east end carries a heavier burden of type 2 diabetes than the city's western suburbs, and the gap is roughly twofold between the most and least deprived areas. That figure is repeated across Scottish health surveys and is not in serious dispute. What receives less attention is the liver sitting underneath the diagnosis.

Metabolic dysfunction-associated steatotic liver disease, the condition until recently called non-alcoholic fatty liver disease, is present in a majority of people with type 2 diabetes. It produces few symptoms until fibrosis is advanced. Tiredness and vague upper abdominal discomfort are the usual complaints, and most patients report nothing at all.

The same biology operates in Bearsden and in Parkhead. What differs is the timing of exposure, the density of cheap calories, the number of hours available for cooking, and the point at which someone finally gets a blood test. Deprivation does not change the mechanism. It changes the dose and the delay.

How the Liver Becomes a Fat Store

Hepatic mitochondria normally oxidise fatty acids at a rate that matches supply. When calories arrive faster than that machinery can clear them, the surplus is re-esterified into triglycerides and stored in hepatocytes. The liver is a buffer, and the buffer has a ceiling.

Insulin resistance accelerates the process. In a resistant liver, insulin fails to suppress gluconeogenesis, so the organ keeps manufacturing glucose while fat accumulates. Hyperinsulinaemia simultaneously drives de novo lipogenesis, converting carbohydrate into new fat. The liver ends up producing sugar and storing lipid at the same time.

Visceral adipose tissue contributes its own stream of free fatty acids directly into the portal circulation, so the liver receives a concentrated dose rather than a diluted one. Macrophages follow. Chronic low-grade inflammation settles in, and the organ shifts from a metabolic buffer to an inflamed depot. A related piece on this site describes the same process appearing at lower body weights in urban Indian populations.

The Two-Way Street of Fat and Fibrosis

Injured hepatocytes release signals that activate hepatic stellate cells, which sit quietly in the space between sinusoids until called upon. Once activated, they lay down collagen. Early fibrosis is reversible. Once bridging fibrosis forms, the architecture of the liver has changed and the change tends to persist.

Fibrosis raises portal pressure and stiffens the organ. Hepatic insulin clearance falls because fewer functioning hepatocytes remain to extract insulin from portal blood. Peripheral insulin levels climb further, which drives more lipogenesis and more fat storage. The loop tightens in both directions.

Glucose output rises unchecked overnight, which is why fasting glucose can drift upward for years before a diagnosis is made. By the time a patient presents with fatigue or a routine blood test flags raised transaminases, the process may have been running for a decade. Fibrosis staging, not the amount of fat, predicts who develops cirrhosis.

There is a further consequence that rarely gets an airing in a ten-minute review. Advanced fibrosis changes what can safely be prescribed. Several glucose-lowering agents require dose adjustment or avoidance once hepatic impairment is established, and the metformin threshold that matters in practice is the one written into the formulary rather than the one in the guideline summary. A patient whose fibrosis was never staged is a patient whose medication list has never been checked against it. The scan that would settle the question is not always the scan that gets requested.

Why Deprivation Accelerates the Damage

Energy-dense food is cheaper per calorie than the alternatives, and it is engineered for palatability in a way that a bag of carrots is not. A pound spent in a discount freezer buys considerably more calories than the same pound spent on fresh produce. That is an economic fact, not a character judgement.

Chronic financial stress raises cortisol, and cortisol raises insulin resistance. Shift work disrupts circadian control of hepatic metabolism, so a night-shift worker may eat at hours when the liver is least prepared to handle a glucose load. Time poverty removes the two interventions that work best, which are cooking from raw ingredients and sustained physical activity.

Diagnosis often arrives late. Raised liver enzymes are frequently found incidentally during an emergency admission or a work medical, by which point fibrosis may already be significant. The objection worth stating plainly is that individual willpower framing fails here. Telling a patient on a zero-hours contract to batch-cook and attend a gym is advice that costs money and hours they do not have.

Alcohol complicates the picture in ways that are easy to handle badly. The old diagnostic labels drew a hard line between alcohol-related and metabolic liver disease, and the line was never biologically clean. Current terminology deliberately allows for both factors to be recorded together, because a patient can carry metabolic fat and drink above safe limits at the same time. In deprived areas, where heavy drinking and central obesity often coexist, the combined insult to the liver is more than additive in practice. Asking about units in the same breath as asking about sugary drinks is not moralising. It is the difference between treating half a problem and treating the whole of it.

The Clinic Gap in Affluent Areas

Private transient elastography, the scanning technique that measures liver stiffness, is available in Glasgow for a fee and can detect steatosis before enzymes rise. Patients who can pay for it often arrive at a consultation already knowing their fibrosis score. That changes the conversation.

Specialist dietitian appointments in the private sector cost more per hour than many patients earn in a day, and the waiting list for NHS dietetics is measured in months. Affluent patients also present differently: a normal BMI does not exclude fatty liver, and lean metabolic disease still carries fibrosis risk. A slim patient with a raised FIB-4 score is easy to reassure wrongly.

Access shapes the speed of detection rather than the underlying biology. This site has argued elsewhere that inhaled medication costs the same while admissions diverge by district, and the pattern holds here. The disease is identical. The trajectory is not.

There is a trade-off buried in this that deserves naming. Widening access to elastography would find more fibrosis earlier, and earlier fibrosis is the stage at which intervention still changes the outcome. But a scan without a route into dietetics, structured weight support or hepatology follow-up generates anxiety and little else. The scan is the cheap part. The capacity behind it is the expensive part, and it is the part that is scarcest in the postcodes where the burden is heaviest. Screening programmes that ignore this produce a longer list of people who know they are at risk and no more people who are being treated.

Practical Steps for the Consultation

Ask specifically about sugar-sweetened drinks, including the volume consumed per day, and about shift patterns. Both are modifiable and both are routinely missed in a ten-minute appointment.

Calculate a FIB-4 score from age, AST, ALT and platelet count as a first-pass fibrosis screen. It costs nothing, uses existing bloods, and identifies the patients who need referral rather than reassurance.

Offer one or two dietary swaps that fit the patient's actual budget and kitchen, such as replacing fizzy drinks with water or swapping a daily takeaway for a supermarket meal deal. Broad lifestyle advice tends to produce no change.

• Refer patients with a FIB-4 above the age-adjusted threshold to hepatology rather than repeating liver enzymes in a year.
• Signpost community weight management programmes that are free at the point of use, and check whether the patient can actually reach the venue.
• Recheck liver enzymes and HbA1c after roughly three months, and treat a rising trend as a reason to escalate.
• Review the medication list against the fibrosis stage you have, not the one you assume, and revisit it if the stage turns out to be higher.

None of this closes the gap between postcodes. It shortens the delay between the fat arriving in the liver and someone acting on it, which is the part a consultation can still influence.

This article is informational and does not constitute personalised medical advice. Anyone with concerns about liver health or blood sugar should consult their own clinician.